Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
BT Slingsby
AddedMar 31, 2024
UpdatedMay 31, 2026
BT Slingsby

BT Slingsby

Founder, Catalys Pacific

CrunchbaseLinkedIn

BT Slingsby's Career

Catalys Pacific
Catalys Pacific

ward area of Tokyo, Tokyo, JP

Founder
Global Health Innovative Technology Fund
Global Health Innovative Technology Fund

Tokyo, Tokyo, JP

Founder
Exalys Therapeutics
Exalys Therapeutics

San Diego, CA, US

Co-Founder
Pathalys Pharma
Pathalys Pharma

Raleigh, NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

BT Slingsby's Career

Catalys Pacific
Catalys Pacific
Investment FirmInvestment Firm62019ward area of Tokyo, Tokyo, JP
Founder
Global Health Innovative Technology Fund
Global Health Innovative Technology Fund
202013Tokyo, Tokyo, JP
Founder

Similar to Global Health Innovative Technology Fund

Mitsubishi Electric Innovation FundMitsubishi Electric Innovation FundMarunouchi, Tokyo, JPInvestingMitsubishi Electric Innovation FundMarunouchi, Tokyo, JP

Tokyo-based ME Innovation Fund links Mitsubishi Electric Group with companies, co-creating world-changing technologies.

50
Global health sciences venture fundGlobal health sciences venture fundVancouver, British Columbia, CAHealthcare, Medicalest. 2016Global health sciences venture fundVancouver, British Columbia, CA · est. 2016

Leading Vancouver-based medical organization fueling life science innovation globally.

50
Exalys Therapeutics
Exalys Therapeutics
Series A$15M322018San Diego, CA, US
Co-Founder

Leadership at Exalys Therapeutics

Takeshi TakahashiTakeshi TakahashiCo-Founder
Rick OrrRick OrrCEO

Similar to Exalys Therapeutics

Aristea TherapeuticsAristea TherapeuticsSan Diego, CA, USDrugsest. 2018Aristea TherapeuticsSan Diego, CA, US · est. 2018

Aristea Therapeutics: Developing novel drugs for autoimmune and inflammatory diseases.

Series B · $117.6M75
Halia TherapeuticsHalia TherapeuticsSalt Lake City, UT, USTherapeuticsest. 2017Halia TherapeuticsSalt Lake City, UT, US · est. 2017

Halia Therapeutics: Preclinical biopharma firm innovating therapies for inflammatory and neurological disorders.

Series C · $47.2M11
Sonexa TherapeuticsSonexa TherapeuticsSan Diego, CA, USDrugsest. 2007Sonexa TherapeuticsSan Diego, CA, US · est. 2007

Sonexa Therapeutics, a California-based biotech firm, develops drugs for Alzheimer's and related disorders.

Public · $41.2M30
Pathalys Pharma
Pathalys Pharma

Raleigh, NC, US

Board Member· Board

BT Slingsby's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to BT Slingsby

David StirlingDavid StirlingCo-Founder · BiotheryxBob BalteraBob BalteraBoard Member · InipharmTerry ColipTerry ColipCo-Founder · Cell PointTariq KassumTariq KassumCEO · Celsius TherapeuticsDonald HawkinsDonald HawkinsFounder · CitySmartKevin SlawinKevin SlawinFounder · Rapha Capital Management